Note 12. Stock-Based Compensation

Stock-Based Compensation Expense

Stock-based compensation is recorded in the consolidated statements of operations as follows (in thousands):

 

 

 

For the Years Ended December 31,

 

 

 

2025

 

 

2024

 

Cost of goods sold

 

$

216

 

 

$

311

 

Research and development

 

 

715

 

 

 

1,379

 

Sales and marketing

 

 

226

 

 

 

379

 

General and administrative

 

 

1,807

 

 

 

2,566

 

Total stock-based compensation expense

 

$

2,964

 

 

$

4,635

 

 

Stock Options

The vesting period for stock options granted to employees is generally one to four years. All stock options granted under the 2016 Plan have a maximum contractual term of ten years.

Commencing in 2019, on the first trading day in February, each non-employee member of the board of directors will receive an annual award of stock options with a grant date fair value of $30,000 (or $45,000 for the chairperson of the board of directors), calculated as of the date of grant in accordance with the Black-Scholes-Merton option-pricing model.

The grant-date fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The weighted average assumptions for grants during the years ended December 31, 2025 and 2024 are provided in the following table:

 

 

 

For the Years Ended December 31,

 

 

 

2025

 

 

2024

 

Expected dividend yield

 

 

0

%

 

 

0

%

Expected volatility

 

 

66.1

%

 

 

68.7

%

Expected term (years)

 

 

4.3

 

 

 

4.1

 

Risk-free interest rate

 

 

4.1

%

 

 

4.2

%

 

 

A summary of the Company’s stock option activity is as follows (shares in thousands):

 

 

 

 

 

Weighted Average

 

 

 

 

 

Number of
stock options

 

 

Exercise
price

 

 

Remaining contractual term (years)

 

Aggregate Intrinsic Value (in thousands)

 

Balance at December 31, 2024

 

 

2,376

 

 

$

9.12

 

 

 

5.9

 

$

2,357

 

Granted

 

 

308

 

 

$

4.56

 

 

 

 

 

 

Exercised

 

 

(111

)

 

$

1.66

 

 

 

 

 

 

Expired/Forfeited

 

 

(155

)

 

$

6.05

 

 

 

 

 

 

Balance at December 31, 2025

 

 

2,418

 

 

$

9.07

 

 

 

5.5

 

$

169

 

 

 

 

 

 

 

 

 

 

 

 

 

Vested and exercisable at December 31, 2025

 

 

1,901

 

 

$

10.15

 

 

 

4.7

 

$

117

 

Vested and expected to vest at December 31, 2025

 

 

2,418

 

 

$

9.07

 

 

 

5.5

 

$

169

 

During the years ended December 31, 2025 and 2024, the Company received proceeds of $0.2 million and $0.1 million respectively from the exercise of options.

The weighted average grant-date fair values of options granted during the years ended December 31, 2025 and 2024 were $2.50 and $2.90 per share, respectively. The grant-date fair value of each option award is estimated on the date of grant using the Black-Scholes-Merton option-pricing model. The grant date fair value of shares vested during the years ended December 31, 2025 and 2024 was $1.2 million and $1.4 million, respectively. For stock options vested and expected to vest, the aggregate intrinsic value as of December 31, 2025 and 2024 was $0.2 million and $2.4 million, respectively.

As of December 31, 2025, there was $1.1 million of unrecognized compensation cost related to unvested stock options granted under the Company’s equity plans that is expected to be recognized over the next 1.8 years.

Restricted Stock Units

The following table summarizes the Company’s restricted stock unit activity (shares in thousands):

 

 

Restricted
stock units

 

 

Weighted average grant date fair value

 

Balance at December 31, 2024

 

 

835

 

 

$

5.95

 

Grants

 

 

559

 

 

$

4.39

 

Vested and released

 

 

(376

)

 

$

6.08

 

Forfeited

 

 

(132

)

 

$

3.27

 

Balance at December 31, 2025

 

 

886

 

 

$

5.13

 

Commencing in 2019, on the first trading day in February of each year, each non-employee member of the board of directors receives a number of restricted stock unit as is determined by dividing $30,000 (or $45,000 for the chairperson of the board of directors) by the 30-trading-day trailing average closing share price of the Company's common stock preceding the date of grant.

As of December 31, 2025, there was $2.5 million of total unrecognized stock-based compensation expense related to non-vested restricted stock units which is expected to be recognized over a remaining weighted-average vesting period of 2.1 years.

The Company currently uses authorized and unissued shares to satisfy share award exercises.

Performance Stock Units

The following table summarizes the Company's PSU activity during the period indicated (shares in thousands):

 

 

 

Performance
stock units

 

 

Weighted average grant date fair value

 

Balance at December 31, 2024

 

 

110

 

 

$

1.79

 

Grants

 

 

 

 

$

 

Vested and released

 

 

 

 

$

 

Forfeited

 

 

(110

)

 

$

 

Balance at December 31, 2025

 

 

 

 

$

 

Service as well as market and performance conditions determine the number of PSUs that the holder will earn from 0% to 150% of the target number of shares. The percentage received is based on the Company common stock price targets over a three-year service period. Additionally, the Company must achieve or exceed 75% of the year to date revenue target measured at the end of the quarter in which the price target is achieved. The market conditions have not currently been met. As of December 31, 2025, there were no PSU grants outstanding.

Share-Settled Obligation

Share-settled compensation to the Board of Directors and consultants were incurred and recognized as stock-based compensation expense and recorded in accrued expenses. Within ninety days after the calendar year-end, the liabilities are settled in RSU grants and vest on the grant date. The share-settled obligations were $0.1 million and $0.8 million as of December 31, 2025 and 2024, respectively.

Employee Stock Purchase Plan (ESPP)

The Company maintains the 2016 Employee Stock Purchase Plan (ESPP) that provides employees an opportunity to purchase common stock through payroll deductions. The ESPP is implemented through consecutive 6-month offering periods commencing on March 1 and September 1 of each year. The purchase price is set at 85% of the fair market value of the Company's common stock on either the first or last trading day of the offering period, whichever is lower. Annual contributions are limited to the lower of 20% of an employee's eligible compensation or such other limits as apply under Section 423 of the Internal Revenue Code. The ESPP is intended to qualify as an employee stock purchase plan for purposes of Section 423 of the Internal Revenue Code.

Based on the 15% discount and the fair value of the option feature of the ESPP, it is considered compensatory. Compensation expense is calculated using the fair value of the employees’ purchase rights under the Black-Scholes model. The Company currently uses authorized and unissued shares to satisfy share purchases under the ESPP.

During the year ended December 31, 2025, the Company received $0.2 million from the issuance of 43,562 shares under the ESPP, as compared to $0.2 million from the issuance of 45,809 shares during the year end December 31, 2024.

About Stock Compensation Disclosures

Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.

Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.